非阿司匹林类非甾体抗炎药与皮肤癌发病风险:Meta分析

发布时间：2018-06-13 01:16

本文选题：非阿司匹林类非甾体抗炎药 + 皮肤癌　；参考：《肿瘤防治研究》2014年08期

【摘要】：目的评价非阿司匹林类非甾体抗炎药与皮肤癌发病风险的关系。方法检索PubMed(Medline),EMBASE,BIOSIS,Cochrane图书馆,中国知网数据库(CNKI)获取有关非阿司匹林类非甾体抗炎药与皮肤癌发病风险的研究。按照纳入标准进行文献筛查、质量评价和资料提取。应用Stata软件计算总体OR值及95%置信区间,并进行偏倚分析。当异质性可以接受时,选用固定效应模型对各研究原始数据进行合并。结果纳入非阿司匹林类非甾体抗炎药与皮肤癌发病风险的相关临床研究文献10篇,共12个独立研究,累计皮肤癌患者482 264例,合并分析结果:OR值为1.00,95%CI:0.98~1.02。结论无足够的证据证明非阿司匹林类非甾体抗炎药与皮肤癌发病风险相关。仍需大规模临床随机对照试验来证实该结果。
[Abstract]:Objective to evaluate the relationship between non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of skin cancer. Methods A study on non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of skin cancer was obtained by searching the PubMeden Medline EMBASE Bios Cochrane Library and CNKI. Document screening, quality evaluation and data extraction according to inclusion criteria. Total OR and 95% confidence interval were calculated by Stata software and bias analysis was carried out. When heterogeneity is acceptable, fixed effect models are used to merge the original data. Results there were 10 clinical studies on non-aspirin non-steroidal anti-inflammatory drugs and the risk of skin cancer. There were 12 independent studies in which there were 482,264 patients with skin cancer. The combined analysis showed that the OR value of the combined analysis was 1.0095 CI: 0.98 + 1.02. Conclusion there is insufficient evidence that non-aspirin non-steroidal anti-inflammatory drugs are associated with the risk of skin cancer. Large-scale randomized controlled trials are still needed to confirm the results.
【作者单位】：南方医科大学南方医院肝脏肿瘤中心;南方医科大学肿瘤中心;南方医科大学中西医结合医院肿瘤科;
【基金】：广东省自然科学基金重点项目(10251051501000008)
【分类号】：R739.5

【相似文献】